57,406 Shares in Novo Nordisk A/S $NVO Purchased by Capital Advisory Group Advisory Services LLC

Capital Advisory Group Advisory Services LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 57,406 shares of the company’s stock, valued at approximately $3,185,000. Novo Nordisk A/S makes up 1.0% of Capital Advisory Group Advisory Services LLC’s portfolio, making the stock its 26th largest holding.

Other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the last quarter. NewSquare Capital LLC lifted its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth about $37,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $39,000. Finally, Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.
• Positive Sentiment: Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.
• Positive Sentiment: U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.
• Neutral Sentiment: Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.
• Neutral Sentiment: High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.
• Negative Sentiment: Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.
• Negative Sentiment: Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. Morgan Stanley restated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. HSBC reiterated a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Finally, CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $56.21.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $62.32 on Monday. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a market capitalization of $278.26 billion, a price-to-earnings ratio of 18.12 and a beta of 0.66. The company has a 50-day simple moving average of $50.85 and a 200 day simple moving average of $54.87. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.